JC Virus Reactivation Should Be Considered in Late Neurotoxicity Associated with Bispecific Antibody Therapy: A Comment. Comment on Bangolo et al. Comprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies. Cancers 2025, 17, 282

May 8, 2026CancersOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

This comment aims to highlight the potential role of JC virus reactivation in neurotoxicity associated with bispecific antibody therapy.
Commentary on a comprehensive review by Bangolo et al. regarding toxicities in CAR T-cell and bispecific antibody therapies.
Analysis focuses on late neurotoxic effects linked to these treatments.
Emphasizes the need for awareness of potential JC virus reactivation.
Underscores the importance of considering JC virus reactivation in patients experiencing late neurotoxicity.
Calls for further research on the correlation between JC virus reactivation and neurotoxicity in treatments.
Provides insights to improve clinical management of patients undergoing bispecific antibody therapy.

We only have this paper's title and publication details.

Comment discusses JC virus reactivation and its link to neurotoxicity in hematologic malignancies treatment, suggesting clinical awareness.

No takes yet. Share an insight, caveat, or question.

İltar et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share